Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 4:30:1-6.
doi: 10.1016/j.jor.2022.02.003. eCollection 2022 Mar-Apr.

The efficacy and cost-effectiveness of enoxaparin versus rivaroxaban in the prevention of venous thromboembolism following total hip or knee arthroplasty: A meta-analysis

Joshua Xu  1   2 , David Chang  3 , Juanita Chui  2 , Jacob Cao  2   4 , Jonathan Negus  2   3
Affiliations

The efficacy and cost-effectiveness of enoxaparin versus rivaroxaban in the prevention of venous thromboembolism following total hip or knee arthroplasty: A meta-analysis

Joshua Xu et al. J Orthop. .

Abstract

Introduction: Thromboprophylaxis following total hip and knee arthroplasty is variable across institutions, but commonly consists of enoxaparin, and more recently rivaroxaban. We aimed to analyze the current evidence on the efficacy, safety and cost-effectiveness of rivaroxaban versus enoxaparin for thromboprophylaxis following TKA or THA.

Methods: This study was conducted according to PRISMA guidelines. Electronic database searches were performed using three databases from their dates of inception to June 2020. Relevant randomized controlled studies were identified, with data extracted and analyzed.

Results: From eight studies, 13,384 patients were included, with 5700 undergoing TKA and 7684 undergoing THA. There were 6629 patients receiving rivaroxaban and 6755 patients receiving enoxaparin. From the total cohort, rivaroxaban was associated with significantly lower rates of major VTE (p = 0.009) and DVT (p < 0.001) when compared to enoxaparin. There was no significant difference in bleeding complications between rivaroxaban and enoxaparin groups (p = 0.14). Subgroup analysis of patients undergoing THA demonstrated that rivaroxaban reduced risk of major VTE (p = 0.002) and DVT (p = 0.01) with no significant differences in any other complications. For those undergoing TKA, rivaroxaban significantly reduced the risk of DVT (p < 0.001) but was associated with higher rates of post-operative blood transfusion (p = 0.03). Cost-analysis revealed that rivaroxaban was superior to enoxaparin, with the medication cost needed to prevent one DVT being $1081 and $432 less with rivaroxaban for THA and TKA respectively.

Conclusions: Rivaroxaban may be a safe and cost-effective alternative to enoxaparin for routine thromboprophylaxis following total knee or hip arthroplasty.

Keywords: Cost; DVT; Embolism; Enoxaparin; Rivaroxaban; Thromboprophylaxis; VTE.

PubMed Disclaimer

Conflict of interest statement

None of the authors have any conflicts of interest to disclose.

Figures

Fig. 1
Fig. 1
PRISMA flow chart of systematic review assessing the efficacy and safety of enoxaparin vs rivaroxaban thromboprophylaxis.
Fig. 2
Fig. 2
Meta-analysis of the primary efficacy outcomes comparing rivaroxaban with enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a) Major venothrombotic event b) Deep vein thrombosis c) Pulmonary embolism.
Fig. 3
Fig. 3
Meta-analysis of the primary safety outcomes comparing rivaroxaban with enoxaparin for thromboprophylaxis after total hip or knee arthroplasty. a) Major bleeding b) Any bleeding c) Blood transfusion.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Falck-Ytter Y., Francis C.W., Johanson N.A., et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of chest Physicians evidence-based clinical Practice guidelines. Chest. 2012;141:e278S–e325S. - PMC - PubMed
    1. Geerts W.H., Pineo G.F., Heit J.A., et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on antithrombotic and thrombolytic therapy. Chest. 2004;126:338S–400S. - PubMed
    1. Mohr D.N., Silverstein M.D., Murtaugh P.A., Harrison J.M. Prophylactic agents for venous thrombosis in elective hip surgery. Meta-analysis of studies using venographic assessment. Arch Intern Med. 1993;153:2221–2228. - PubMed
    1. Friedman R.J. Extended thromboprophylaxis after hip or knee replacement. Orthopedics. 2003;26:s225–s230. - PubMed
    1. Shahi A., Bradbury T.L., Guild G.N., 3rd, Saleh U.H., Ghanem E., Oliashirazi A. What are the incidence and risk factors of in-hospital mortality after venous thromboembolism events in total hip and knee arthroplasty patients? Arthroplast Today. 2018;4:343–347. - PMC - PubMed

LinkOut - more resources